Form 4: EcoR1 Capital Increases Stake in iTeos Therapeutics with Recent Stock Purchases

EcoR1 Capital, a significant shareholder of iTeos Therapeutics, has increased its holdings through multiple open market purchases of common stock.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., has reported changes in their beneficial ownership of iTeos Therapeutics, Inc. (ITOS) common stock.
• On May 14, 2025, Qualified Fund purchased 1,658,978 shares at a weighted average price of $7.4055, with prices ranging from $7.35 to $7.60.
• Following this transaction, Qualified Fund held 6,926,788 shares.
• On May 15, 2025, Qualified Fund purchased an additional 3,300,000 shares at $8 per share.
• After the second transaction, Qualified Fund held 10,020,210 shares of iTeos Therapeutics' common stock.
• EcoR1 Capital, as the investment advisor to the Funds, may be deemed to indirectly beneficially own these shares, and Mr. Nodelman, as the control person of EcoR1, may also be deemed to indirectly beneficially own them.
• The filers disclaim beneficial ownership except to the extent of their respective pecuniary interests.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a significant shareholder is increasing their investment, suggesting confidence in the company's prospects. However, it's a routine filing, so the impact is limited.

Positives

• Increased investment by a major shareholder could signal confidence in iTeos Therapeutics' future prospects.

Industry Context

Form 4 filings are standard disclosures for significant shareholders, providing transparency into their trading activities. Increased ownership by investment firms like EcoR1 Capital is often viewed positively by the market.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for individuals or entities owning more than 10% of a company's shares, or who are considered insiders, similar to filings made by major shareholders in companies like Pfizer, Moderna, or BioNTech.
• The level of detail provided in this filing is consistent with industry standards for disclosing changes in beneficial ownership.

Stakeholder Impact

• Increased institutional ownership could be viewed positively by shareholders.
• The transactions may have a minor impact on the stock price in the short term.

Key Dates

Keywords

iTeos Therapeutics, EcoR1 Capital, Oleg Nodelman, Qualified Fund, Beneficial Ownership, Stock Purchase, ITOS